JP5577020B2 - 代謝活性を有する微生物及びその製造方法 - Google Patents
代謝活性を有する微生物及びその製造方法 Download PDFInfo
- Publication number
- JP5577020B2 JP5577020B2 JP2007532974A JP2007532974A JP5577020B2 JP 5577020 B2 JP5577020 B2 JP 5577020B2 JP 2007532974 A JP2007532974 A JP 2007532974A JP 2007532974 A JP2007532974 A JP 2007532974A JP 5577020 B2 JP5577020 B2 JP 5577020B2
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- preparation
- range
- total amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000005700 microbiome Species 0.000 title claims description 35
- 230000002503 metabolic effect Effects 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 241000894006 Bacteria Species 0.000 claims description 125
- 230000012010 growth Effects 0.000 claims description 116
- 239000000758 substrate Substances 0.000 claims description 81
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 72
- 238000002360 preparation method Methods 0.000 claims description 71
- 230000001580 bacterial effect Effects 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 51
- 239000004310 lactic acid Substances 0.000 claims description 40
- 235000014655 lactic acid Nutrition 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 150000001720 carbohydrates Chemical class 0.000 claims description 27
- 235000014633 carbohydrates Nutrition 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 235000000346 sugar Nutrition 0.000 claims description 26
- 238000003860 storage Methods 0.000 claims description 18
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 241000194031 Enterococcus faecium Species 0.000 claims description 10
- 244000199866 Lactobacillus casei Species 0.000 claims description 10
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 229940017800 lactobacillus casei Drugs 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 229940121375 antifungal agent Drugs 0.000 claims description 7
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 150000002772 monosaccharides Chemical class 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 150000008163 sugars Chemical class 0.000 claims description 6
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- 241000894007 species Species 0.000 description 16
- 241000209140 Triticum Species 0.000 description 14
- 235000021307 Triticum Nutrition 0.000 description 14
- 235000021310 complex sugar Nutrition 0.000 description 14
- 235000021309 simple sugar Nutrition 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 12
- 235000013330 chicken meat Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 9
- 238000005360 mashing Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003833 bile salt Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000035784 germination Effects 0.000 description 7
- 239000006872 mrs medium Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940093761 bile salts Drugs 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000194033 Enterococcus Species 0.000 description 5
- 240000005979 Hordeum vulgare Species 0.000 description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
- 229940038773 trisodium citrate Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 4
- 235000019801 trisodium phosphate Nutrition 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000272534 Struthio camelus Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000031787 nutrient reservoir activity Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010065611 Intestinal congestion Diseases 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ONXOKWFYBIQOFQ-VSXSCALHSA-N ac1l4s0d Chemical compound OS(O)(=O)=O.O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O.O[C@@H]1[C@H](O)[C@@H](O)[C@@H](SC)O[C@@H]1[C@@H]([C@@H](C)O)NC(=O)[C@H]1N(C)C[C@H](C(C)C)C1 ONXOKWFYBIQOFQ-VSXSCALHSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
(参考文献)
F. Fonseca, C. Beal, and G. Corrieu, J. Dairy Res. 67(1): 83-90, 2000. M. L. F. Murga, A. P. D. Holgado, and G. F. de Valdez. Cryobiology 36 (4): 315-319、1998. J. Hamilton-Miller. Lancet 355 (9201): 413-414, 2000. Kunze, W. Technology Brewing and Malting (1996).(期待される健康上の利点) Collins, J. K., O’Sullivan, G. and Shanahan, F. (1996) Gut flora and health - past, present and future, Royal Society of Medicine Press Limited, London. D. Haller, C. Bode, and W. P. Hammes. Microbiol. Immunol. 43 (10): 925-935, 1999.C. Hessle, L. A. Hanson, and A. E. Wold. Clin. Exp. Immunol. 116 (2): 276-282, 1999. E. Isolauri, Y. Sutas, P. Kankaanpaa, H. Arvilommi, and S. Salminen. Am. J. Clin. Nutr. 73 (2): 444S-450S, 2001. M. Miettinen, S. Matikainen, J. Vuopio-Varkila, J. Pirhonen, K. Varkila, M. Kurimoto, and I. Julkunen, Infect. Immun. 66 (12): 6058-6062, 1998. A. E. Wold and I. Adlerberth. Adv. Exp. Med. Biol. 478: 77-93, 2000.(血液化学) J. W. Anderson and S. E. Gilliland. J. Am. Coll. Nutr. 18 (1): 43-50, 1999. H. Bukowska, J. Pieczul-Mroz, M. Jastrzebska, K. Chelstowski, and M. Naruszewicz, Atherosclerosis 137 (2): 437-438, 1998. I. De Smet, P. De Boever, and W. Verstraete, Br. J. Nutr. 79 (2): 185-194, 1998. T. Endo, M. Nakano, S. Shimizu, M. Fukushima, and S. Miyoshi. Biosci. Biotechnol. Biochem. 63 (9): 1569-1575, 1999. H. Kikuchi-Hayakawa, N. Onodera, S. Matsubara, E. Yasuda, Y. Shimakawa, and F. Ishikawa. Br. J. Nutr. 79 (1): 97-105, 1998. H. Kikuchi-Hayakawa, H. Shibahara-Sone, K. Osada, N. Onodera-Masuoka, F. Ishikawa, and M. Watanuki. Biosci. Biotechnol. Biochem. 64 (3): 466-475, 2000. F. A. M. Klaver and R. van der Meer, The Assumed Appl. Environ. Microbiol. 59 (4): 1120-1124, 1993. B. K. Mital and S. K. Garg. Crit. Rev. Microbiol. 21 (3): 175-214, 1995. G. R. J. Taylor and C. M. Williams. Br. J. Nutr. 80 (4): S225-S230, 1998.(ガンの治療と予防) Y. Aso, H. Akaza, T. Kotake, T. Tsukamoto, K. Imai, and S. Naito. Eur. Urol. 27: 104-109, 1995. R. Balansky, B. Gyosheva, G. Ganchev, Z. Mircheva, S. Minkova, and G. Georgiev. Cancer Lett. 147 (1-2): 125-137, 1999. L. J. Brady, D. D. Gallaher, and F. F. Busta. J. Nutr. 130 (2): 410S-414S, 2000. D. D. Gallaher and J. Khil. J. Nutr. 129 (7): 1483S-1487S, 1999. B. R. Goldin. Br, J. Nutr. 80 (4): S203-S207, 1998. S. L. Gorbach, Am. J .Gastroenterol. 95 (1): S2-S4, 2000.K. Hirayama and J. Rafter, Antonie Van Leeuwenhoek - International Journal of Microbiology 76 (1): 391-394, 1999. K. Hirayama and J. Rafter. Microbe. Infect. 2 (6): 681-686, 2000. W. H. Ling. Nutr. Res. 15 (3): 439-454, 1995. G. H. Mclntosh, P. J. Royle, and M. J. Playne, Nutr. Cancer. 35 (2): 153-159, 1999. J. J. Rafter. Scand. J. Gastroenterol. 30: 497-502, 1995. B. S. Reddy. Br. J. Nutr. 80 (4): S219-S223, 1998. Rowland, I. R. (1996) "Gut microflora and cancer" in Leeds, A. R. and Rowland, I. R. (eds.) Gut flora and health-past, present and future, Royal Society of Medicine Press Limited, London. M. D. Winters, T. L. Schlinke, W. A. Joyce, S. R. Glore, and M. M. Huycke. Am. J. Gastroenterol. 93 (12): 2491-2500, 1998.(下痢と便秘) T. Arvola, K. Laiho, S. Torkkeli, H. Mykkanen, S. Salminen, L. Maunula, and E. Isolauri, Pediatrics 104 (5): L1-L4, 1999. R. Bennet, S. L. Gorbach, B. R. Goldin, T. W. Chang, B. E. Laughon, W. B. Greenough, and J. G. Bartlett. Nutrition Today 31 (6): 35S-38S, 1996. A. Bomba, R. Nemcova, S. Gancarcikova, R. Herich, and R. Kastel. Adv. Exp. Med. Biol. 473: 185-190, 1999. N. M. De Roos and M. B. Katan. Am. J. Clin. Nutr. 71 (2): 405- 411, 2000. H. L. DuPont. J. Pediatr. 134 (1): 1-2, 1999. S. L. Gorbach. Am. J. Gastroenterol. 95 (1): S2-S4, 2000. M. Heyman, J. Am. Coll. Nutr. 19 (2): 137S-146S, 2000. E. Isolauri, M. Kaila, H. Mykkanan, W. H. Ling, and S. Salminen. Dig. Dis. Sci. 39 (12): 2595-2600, 1994. R. A. Oberhelman, E. H. Gilman, P. Sheen, D. N. Taylor, R. E. Black, L. Cabrera,.A. G. Lescano, R. Meza, and G. Madico, J. Pediatr. 134 (1): 15-20, 1999. R. D. Rolfe. J. Nutr. 130 (2): 396S-402S, 2000. J. Saavedra. Am. J. Gastroenterol. 95 (1): S16-S18, 2000. C. Scarpignato and P. Rampal. Chemotherapy 41 ((suppl 1)): 48-81, 1995.A. V. Shornikova, I. A. Casas, H. Mykkanen, E. Salo, and T. Vesikari. Pediatr. Infect. Dis. J. 16 (12): 1103-1107, 1997. J. A. Vanderhoof, D. B. Whitney, D. L. Antonson, T. L. Hanner, J. V. Lupo, and R. J. Young, J. Pediatr. 135 (5): 564- 568, 1999.(過敏性腸症候群) P. Brigidi, B. Vitali, E. Swennen, G. Bazzocchi, and D. Matteuzzi. Res. Microbiol. 152 (8): 735-741, 2001. K. Niedzielin, H. Kordecki, and B. Birkenfeld. Eur. J. Gastroenterol. Hepatol. 13 (10): 1143-1147, 2001. S. Nobaek, M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. Am. J. Gastroenterol. 95 (5): 1231-1238, 2000.(一般的な総説) Marteau, P. and Rambaud, J-C, (1996) "Therapeutic applications of probiotics in humans" in Leeds, A. R. and Rowland, I. R. (eds.) Gut flora and health-past, present and future, Royal Society of Medicine Press Limited, London. Stark, B. A. and Wilkinson, (eds.) (1989) Probiotics. Theory and Applications, Chalcombe Publications, Bucks, UK.21
具体的には、例えば、製剤の保存中のpHは約4.0に維持される。製剤中のpHは、適当な一種または複数の緩衝液を添加することで適切に調節することができる。好ましい緩衝液としては、例えばクエン酸三ナトリウムやリン酸三ナトリウムの緩衝液があげられる。クエン酸三ナトリウムやリン酸三ナトリウムの緩衝液等の緩衝液の使用法は、文献中に標準法として記載されている。
(A)発芽(モルト化)
{1日目}
オオムギを、そのロットに応じて水中に2〜24時間浸漬した。発芽期における汚染菌の増殖を防ぐために、0.1%(w/v)の次亜塩素酸ナトリウム(漂白剤)を水に加えてもよい。4時間後、水を除き、残った麦粒を10〜30℃の室温で約1日間静置した。
上記麦粒をさらに清澄水に4時間浸漬した。この水及び以降の使用される水に、過酸化水素(0.1%w/v)を加えてもよい。過酸化水素は発芽中の麦粒に酸素を供給するとともに殺菌剤としても作用する。代わりに次亜塩素酸ナトリウムを用いてもよい。4時間後、水を除き、麦粒を約1日間静置した。時々(例えば4時間ごと)、オオムギを攪拌すれば、ガス交換が速まり、酸素が供給され、二酸化炭素が除去されることになるので、オオムギの発芽が促進される。
浸漬、排水、静置のサイクルを、発芽麦粒上の細根の長さが2〜4mmになるまで繰り返した。この成長段階では、麦粒は貯蔵栄養素を代謝するために酵素を産生している。これらの酵素は、マッシュインの際に、増殖培養液の産生に重要な役割を果たす。細根が数ミリメートルの長さに達するまでのこの発芽工程を進め、麦粒に更に大きな変化をもたらせてもよい。しかしながら、この過成長では、栄養素が発芽や発根に使用されるだけで、発酵には用いられない。
発芽が十分に進んだ後、麦粒をローラー製粉機を用いて粉砕した。製粉機は、麦粒が粉末化あるいは完全に扁平化するのではなく、ひび割れる程度に調製した。麦粒がひび割れることにより、マッシュインの際に水が浸入や栄養素の抽出が容易となり、また粉体化していないのでろ過が容易である。
発芽しひび割れした麦粒を、45℃で十分な量の水に浸漬し、混合物を45℃で1時間放置した。
(a)糖質の分析:
全糖質含量を、グルコースを比較標準物質として用いて、フェノール硫酸法により測定した(Dubois, M., Gilles, K. A., Hamilton、J. K., Rebers, P. A. and Smith, F. (1956) Analytical Chemistry, vol. 28, p.350)。
基質中の全糖質は20〜40mg/mlの範囲にある。
還元糖は5〜20mg/mlの範囲にある。
総タンパク質量を、ウシ血清アルブミンを比較標準物質として、二種の測定法により測定した。
(i)ビウレット試薬(Itzhaki,R. F & Gill, D. M. (1964) Analytical Biochemistry, Vol. 9., p.401-410)。
(ii)オオニシ及びバールによる改良ローリー法(Ohnishi, S. T. & Barr, J. K. (1978) Journal of Biological Chemistry Vol. 193, p.265)。
総タンパク質及びペプチド量は1〜2mg/mlの範囲にある。
高分子量ペプチド(5000ダルトン以上)は100〜300μg/mlの範囲にある。
(A)培養
実施例1に従って調製した成長基質を37℃に冷却し、細菌培養物を加えた。好ましい種菌の例としては、凍結乾燥細菌又は液体スタータ・カルチャー(一般的には栄養培地中で1晩培養された1%(v/v)の培養物)があげられる。
(i)エンテロコッカス・フェシウム、ラクトバチルス・プランタラム
(ii)ラクトバチルス・カゼイ
代謝活性培養物の保存有効期間を評価するために、実施例2で得られたエンテロコッカス・フェシウム、ラクトバチルス・プランタラム及びラクトバチルス・カゼイからなる細菌培養物を4℃(±1℃)で保管した。1週間おきに試料を採取し、0.1%(w/v)ペプトン水で段階希釈した試料100μlを寒天培地上に広げた。シャーレを約48時間、約37℃で培養し、細菌のコロニーを数えた。
下記の結果は、本発明方法で調製された細菌の保存有効期間を1週間1ミリリットルあたりのコロニー形成単位数(図2も参照)として示したものである。バッチA及びBはここに記載された方法と同じ方法で行ったが、異なった日に調製された。
E.f:エンテロコッカス・フェシウム
L.p:ラクトバチルス・プランタラム
L.c:ラクトバチルス・カゼイ
LAB:乳酸菌
Cfu per ml:1ミリリットル当たりのコロニー形成単位数
この一連の実験においては、ラクトバチルス・プランタラムの単一株を培地に接種して用いた。約37℃での増殖を、600nmでの吸光度により測定した(また寒天培地上に希釈液を塗布しコロニー数を数える方法によっても評価した)。
細菌をMRS培地に接種し、その増殖を観測した(x1=最終濃度で1×107cfu/mlの種菌;x2=2×107cfu/ml)。結果を図1aに示す。第一の成長曲線は、良好な環境においては、液体培養物が凍結乾燥製剤より増殖が早いことを示している。凍結乾燥製剤では、休眠中の細菌が再水和されその代謝活動が再起動するのに時間がかかるためと考えられる。
1%(v/v)の液体培養物又は凍結乾燥細菌の懸濁液を、前もってHClで種々のpHに調節したMRS培地に加えた。細菌をこれらの酸性培地中で1時間培養し、試料をMRS−寒天培地上で計数した。
更に過酷な条件として、「湿」及び「乾」細菌製剤の増殖を下記の条件において比較した。
(a)MRS培地のみ(図1b)
(b)0.5%(w/v)胆汁酸塩(Oxoid L55)を添加したMRS培地(図1c)
(c)pH3.0のMRS培地で1時間培養後、胆汁酸塩を加えたMRS培地で培養(図1d)
・「湿」細菌は「乾」細菌より成長が早い。
・酸への暴露は「湿」細菌より「乾」細菌に、より有害な影響を与える。
・胆汁酸塩は両方の細菌の増殖を阻害するが、「湿」細菌より「乾」細菌に、より有害な影響を与えるようである。
・酸に続く胆汁酸塩での処理による複合的影響で、「湿」細菌は増殖速度が抑えられるが、「乾」細菌は死滅する(寒天培地上でのコロニーの消失により判定)。
(投与及び方法:)
乳酸菌であるE. faecium、L. plantarum、L. casei、L. acidophilusを含む善玉細菌製剤を、ここに記載の方法に従って調製した。善玉細菌製剤により市販の家禽(ブロイラー)の腸内細菌叢を変化させることができるか試験した。
ニワトリに、抗生物質のリンコスペクチンを1日目(日齢)から3日目まで投与した。
4日目は何もしなかった。
5日目、半数の鶏舎には、ニワトリ5000羽あたり1リットルの割合で上記製剤を投与した。残りの鶏舎は対照群とした。
6日目、各群から無作為にニワトリ6羽を選択し、殺し、その腸内細菌叢を調べた。(各群の複数のニワトリの組織試料を保存し、各群から3つの試料を作成した)。
分析対象とした消化器の範囲は、小腸開始部から卵黄嚢の結合部位に至る腸管上部である。
結果を図3に示す。
L1〜L3:善玉菌処置を行ったニワトリ(第1〜3対)
C1〜C3:対象群のニワトリ(第1〜3対)
SI:小腸
cfu:コロニー形成単位数
処理群と対照群とでは、乳酸菌(LAB)数に明らかな相違がみられた。両群の全LAB量は同等であるが、対照群の細菌叢は単一種が優勢であるのに対し、善玉菌処置群のニワトリでは広範な種が混在していた。
本発明による製剤の効果を、ダチョウひな鳥において評価した。孵化4日目の下痢をしているダチョウを用いて、4週間にわたり試験した。1つ目のダチョウ群には本発明による製剤を、2つ目の群には広スペクトル抗生物質を、3つ目の群にはビタミンとアミノ酸のサプリメントを投与した。試験結果によると、本発明の製剤の投与群では抗生物質投与群と比較して死亡率が67%減少し、本製剤を投与することにより、便秘、下痢、腸鬱血、腸運動の異常、腸脱出症などの症状が緩和されていることがわかる。さらに、善玉細菌製剤投与群では対照群と比較して、体重が27%増加した。
別途、慢性腸炎のネコ及びイヌに対する本発明の製剤の影響を検討したところ、正常な腸内細菌叢への回復に有用であることが明らかとなった。
Claims (18)
- 代謝活性のある乳酸菌と、多糖、オリゴ糖、単糖、二糖、タンパク質およびペプチドの混合物からなる成長基質とから構成される製剤であって、その製剤中の乳酸菌が、4±1℃でpHを3.8〜4.5に調節して保存するとき少なくとも5ヶ月間乳酸菌数が一定である近平衡成長状態を示すように、前記糖の総量が20〜40mg/mlの範囲であり、還元糖の総量が5〜20mg/mlの範囲になるようにするとともに、成長基質中の還元糖の割合が全糖質に対して10〜50%(w/w)になるようにし、
前記タンパク質とペプチドの総量が1〜2mg/mlの範囲であり、前記高分子量ペプチドの総量が100〜300μg/mlの範囲であり、
前記乳酸菌がエンテロコッカス・フェシウム(Enterococcus faecium)、ラクトバチルス・プランタラム(Lactobacillus plantarum)及びラクトバチルス・カゼイ(Lactobacillus casei)を含み、
4±1℃でpHを3.8〜4.5に調節して保存するとき、1ミリリットル当たりの乳酸菌数が、少なくとも5ヶ月間、108〜109の範囲に維持されるようにしたことを特徴とする、製剤。 - 前記乳酸菌がラクトバチルス・アシドフィラス(Lactobacillus acidophilus)をさらに含む、請求項1に記載の製剤。
- さらに抗真菌剤を含有する、請求項1または2に記載の製剤。
- さらに抗酸化剤を含有する、請求項1〜3のいずれか一つに記載の製剤。
- 代謝活性のある安定な乳酸菌製剤の調製方法であって、乳酸菌を多糖、オリゴ糖、単糖、二糖、タンパク質およびペプチドの混合物から構成される成長基質中で培養して乳酸菌製剤を調整した後、該製剤を4±1℃に冷却して乳酸菌に近平衡成長状態をとらせて該製剤を4±1℃でpHを3.8〜4.5に調整して保存した場合、乳酸菌製剤中の乳酸菌数が少なくとも5ヶ月間一定であるように、前記糖の総量が20〜40mg/mlの範囲であり、還元糖の総量が5〜20mg/mlの範囲になるようにするとともに、成長基質中の還元糖の割合が全糖質に対して10〜50%(w/w)になるようにし、また、必要に応じて、さらに4±1℃で保存することを含み、
前記タンパク質とペプチドの総量が1〜2mg/mlの範囲であり、前記高分子量ペプチドの総量が100〜300μg/mlの範囲であり、
前記乳酸菌がエンテロコッカス・フェシウム(Enterococcus faecium)、ラクトバチルス・プランタラム(Lactobacillus plantarum)及びラクトバチルス・カゼイ(Lactobacillus casei)を含み、
4±1℃でpHを3.8〜4.5に調節して保存するとき、1ミリリットル当たりの乳酸菌数が、少なくとも5ヶ月間、108〜109の範囲に維持されるようにしたことを特徴とする、代謝活性のある安定な乳酸菌製剤の調製方法。 - 単一の成長基質中で2種の乳酸菌を培養する、請求項5に記載の方法。
- 2種以上の乳酸菌を別々の成長基質中で培養し4±1℃で保存する前に混合する、請求項5または6に記載の方法。
- 代謝活性のある安定な乳酸菌製剤の調製方法であって、4±1℃でpHを3.8〜4.5に調節して保存したとき少なくとも5ヶ月間微生物製剤中の乳酸菌数が一定である近平衡増殖状態となるような濃度で、乳酸菌を多糖、オリゴ糖、単糖、二糖、タンパク質およびペプチドの混合物からなる成長基質に加えて乳酸菌製剤とするにあたり、前記糖の総量が20〜40mg/mlの範囲であり、還元糖の総量が5〜20mg/mlの範囲になるようにするとともに、成長基質中の還元糖の割合が全糖質に対して10〜50%(w/w)になるようにし、必要に応じて該製剤を4±1℃で保存することを含み、
前記タンパク質とペプチドの総量が1〜2mg/mlの範囲であり、前記高分子量ペプチドの総量が100〜300μg/mlの範囲であり、
前記乳酸菌がエンテロコッカス・フェシウム(Enterococcus faecium)、ラクトバチルス・プランタラム(Lactobacillus plantarum)及びラクトバチルス・カゼイ(Lactobacillus casei)を含み、
4±1℃でpHを3.8〜4.5に調節して保存するとき、1ミリリットル当たりの乳酸菌数が、少なくとも5ヶ月間、108〜109の範囲に維持されるようにしたことを特徴とする、代謝活性のある安定な乳酸菌製剤の調製方法。 - 前記乳酸菌がさらにラクトバチルス・アシドフィラス(Lactobacillus acidophilus)を含む、請求項8に記載の方法。
- 前記成長基質の還元糖の総量が5〜15mg/mlの範囲である、請求項8または9に記載の方法。
- 前記製剤の保存前に抗真菌剤を加える、請求項5〜10のいずれか一つに記載の方法。
- 請求項1〜4のいずれか一つに記載の代謝活性のある安定な乳酸菌製剤からなることを特徴とする、動物の飼料。
- 請求項1〜4のいずれか一つに記載の代謝活性のある安定な乳酸菌製剤からなることを特徴とする、ヒト用の食品又は飲料。
- 1種以上の薬学的に許容しうる希釈液、担体、賦形剤と混合された請求項1〜4のいずれか一つに記載の代謝活性のある安定な乳酸菌製剤からなることを特徴とする、医薬品組成物。
- 薬物として使用される、請求項1〜4のいずれか一つに記載の代謝活性のある安定な乳酸菌製剤。
- 請求項1〜4のいずれか一つに記載の代謝活性のある安定な細菌製剤の、哺乳類腸内微生物のバランスを乱す疾病の治療薬製造のための利用。
- 前記腸内微生物バランスを乱す疾病が慢性炎症性腸疾患、潰瘍性大腸炎あるいはクローン病である、請求項16に記載の利用。
- 請求項1〜4のいずれか一つに記載の代謝活性のある安定な細菌製剤の、哺乳類腸内微生物のバランス維持に用いる薬物の製造のための利用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0421448A GB2418431A (en) | 2004-09-27 | 2004-09-27 | Metabolically active micro organisms and methods for their production |
GB0421448.2 | 2004-09-27 | ||
PCT/GB2005/003715 WO2006035218A1 (en) | 2004-09-27 | 2005-09-27 | Metabolically active micro organisms and methods for their production |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008514582A JP2008514582A (ja) | 2008-05-08 |
JP2008514582A5 JP2008514582A5 (ja) | 2008-11-13 |
JP5577020B2 true JP5577020B2 (ja) | 2014-08-20 |
Family
ID=33397330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007532974A Active JP5577020B2 (ja) | 2004-09-27 | 2005-09-27 | 代謝活性を有する微生物及びその製造方法 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8551473B2 (ja) |
EP (2) | EP1794283B1 (ja) |
JP (1) | JP5577020B2 (ja) |
CN (2) | CN100537740C (ja) |
AU (1) | AU2005288751B2 (ja) |
CA (1) | CA2580949C (ja) |
EA (1) | EA012968B1 (ja) |
ES (2) | ES2568955T3 (ja) |
GB (1) | GB2418431A (ja) |
HK (1) | HK1134686A1 (ja) |
NO (1) | NO20072210L (ja) |
NZ (1) | NZ553858A (ja) |
PL (2) | PL1794283T3 (ja) |
WO (1) | WO2006035218A1 (ja) |
ZA (1) | ZA200702398B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2418431A (en) * | 2004-09-27 | 2006-03-29 | Multigerm Uk Entpr Ltd | Metabolically active micro organisms and methods for their production |
SE532899C2 (sv) * | 2007-06-08 | 2010-05-04 | Probi Ab | Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel |
ES2719096T3 (es) * | 2008-11-21 | 2019-07-08 | Cruz Serrano Jose Antonio | Método para obtener una mezcla de probióticos, prebióticos nutrientes con acción simbiótica sinérgica |
WO2013072654A1 (en) | 2011-11-16 | 2013-05-23 | Multigerm Uk Enterprises Ltd. | Ibs treatment |
GB201119774D0 (en) * | 2011-11-16 | 2011-12-28 | Multigerm Uk Entpr Ltd | IBS treatment |
GB201219873D0 (en) * | 2012-11-05 | 2012-12-19 | Multigerm Uk Entpr Ltd | Diverticulitis treatment |
DE102012110612A1 (de) * | 2012-11-06 | 2014-05-08 | Gelita Ag | Kollagenhydrolysat und dessen Verwendung |
CN105296541A (zh) * | 2014-07-30 | 2016-02-03 | 无限极(中国)有限公司 | 燕麦发酵液及其制备方法与作为化妆品原料的应用 |
ES2575828B1 (es) * | 2014-12-31 | 2017-07-07 | Universidad De León | Empleo de probióticos en el incremento de la fertilidad masculina |
GB201501938D0 (en) | 2015-02-05 | 2015-03-25 | Multigerm Uk Entpr Ltd | Probiotic preparation |
CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
CN108315279A (zh) * | 2018-04-09 | 2018-07-24 | 河南科技大学 | 一种植物乳杆菌液体制剂的长时间储存方法 |
EP3810097A1 (en) * | 2018-06-19 | 2021-04-28 | 4D Pharma Research Limited | Dosage form comprising a live biotherapeutic product |
JPWO2020013239A1 (ja) * | 2018-07-10 | 2021-05-13 | 学校法人慶應義塾 | D−プシコース応答性増殖能を有する腸内細菌 |
CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
CN109486713B (zh) * | 2018-12-06 | 2021-03-09 | 福建傲农生物科技集团股份有限公司 | 一种液态复合乳酸杆菌制剂及其制备方法与应用 |
GB201915144D0 (en) * | 2019-10-18 | 2019-12-04 | Multigerm Uk Entpr Ltd | Method of promoting SCFA production by gut microbiota |
WO2021113850A2 (en) * | 2019-12-06 | 2021-06-10 | Nas Bioventures Llc | Onsite installation or manufactured product of eco-friendly bacterial compositions, methods and systems for bioremediation in a short duration in different environments |
AU2022391767A1 (en) | 2021-11-22 | 2024-07-04 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
GB202210523D0 (en) | 2022-07-18 | 2022-08-31 | Multigerm Uk Entpr Ltd | Probiotic compositions and therapeutic uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB906212A (en) * | 1960-08-04 | 1962-09-19 | Lilly Co Eli | The antibiotic valacidin and its salts and methods for producing same |
US3623956A (en) * | 1970-01-21 | 1971-11-30 | Rapidase Sa Soc | Preparation of microbial alkaline protease by fermentation with bacillus subtilis, variety licheniformis |
US3846397A (en) * | 1970-04-06 | 1974-11-05 | J Ernster | Process for utilizing barley malt |
US4464402A (en) * | 1978-04-24 | 1984-08-07 | F.I.N.D. Research Corporation | Process for manufacturing a high protein food material |
US4275164A (en) * | 1979-11-05 | 1981-06-23 | Eastman Kodak Company | Process and nutrient medium for growing microorganism |
EP0189657B1 (en) * | 1984-12-12 | 1989-03-01 | WHITBREAD & COMPANY PLC | A brewing process |
JPS63273469A (ja) * | 1986-12-13 | 1988-11-10 | Kyowa Hakko Kogyo Co Ltd | 乳糖資化性を有する新規微生物 |
DK686187D0 (da) | 1987-12-23 | 1987-12-23 | Hansens Chr Bio Syst | Veterinaert praeparat |
JP2835894B2 (ja) * | 1991-07-26 | 1998-12-14 | 農林水産省食品総合研究所長 | ビフィズス菌増殖促進剤 |
JPH08259450A (ja) * | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
IE960360A1 (en) * | 1996-05-23 | 1997-12-31 | Valdosa Limited | A brewing process |
JP2000515381A (ja) * | 1996-08-05 | 2000-11-21 | モーヘン インターナショナル エヌ.ブイ. | 麦芽種子を用いるアルコール飲料の製造のための改善されたプロセス |
US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
FR2777424B1 (fr) * | 1998-04-15 | 2000-06-16 | Lesaffre & Cie | Levain panaire longue conservation pret a l'emploi |
US6420146B1 (en) * | 2000-03-30 | 2002-07-16 | Council Of Scientific & Industrial Research | Process for the preparation of stable yeast crystals for enhanced production of ethanol |
JP4424643B2 (ja) * | 2002-02-13 | 2010-03-03 | 株式会社バイオバンク | 抗真菌剤の製造方法 |
GB2391554B (en) * | 2002-08-06 | 2005-09-14 | Heineken Ireland Ltd | A stout manufacturing process |
GB2418431A (en) * | 2004-09-27 | 2006-03-29 | Multigerm Uk Entpr Ltd | Metabolically active micro organisms and methods for their production |
-
2004
- 2004-09-27 GB GB0421448A patent/GB2418431A/en not_active Withdrawn
-
2005
- 2005-09-27 US US11/663,877 patent/US8551473B2/en active Active
- 2005-09-27 ES ES05786983.6T patent/ES2568955T3/es active Active
- 2005-09-27 EA EA200700613A patent/EA012968B1/ru not_active IP Right Cessation
- 2005-09-27 CN CNB2005800324851A patent/CN100537740C/zh active Active
- 2005-09-27 CN CN2009101495392A patent/CN101603021B/zh active Active
- 2005-09-27 NZ NZ553858A patent/NZ553858A/en not_active IP Right Cessation
- 2005-09-27 CA CA2580949A patent/CA2580949C/en active Active
- 2005-09-27 EP EP05786983.6A patent/EP1794283B1/en active Active
- 2005-09-27 AU AU2005288751A patent/AU2005288751B2/en active Active
- 2005-09-27 JP JP2007532974A patent/JP5577020B2/ja active Active
- 2005-09-27 EP EP16155521.4A patent/EP3050960B1/en active Active
- 2005-09-27 WO PCT/GB2005/003715 patent/WO2006035218A1/en active Application Filing
- 2005-09-27 ES ES16155521.4T patent/ES2654246T3/es active Active
- 2005-09-27 PL PL05786983.6T patent/PL1794283T3/pl unknown
- 2005-09-27 PL PL16155521T patent/PL3050960T3/pl unknown
-
2007
- 2007-03-22 ZA ZA200702398A patent/ZA200702398B/xx unknown
- 2007-04-27 NO NO20072210A patent/NO20072210L/no not_active Application Discontinuation
-
2010
- 2010-03-15 HK HK10102640.8A patent/HK1134686A1/xx unknown
-
2012
- 2012-09-05 US US13/604,196 patent/US20130011368A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1134686A1 (en) | 2010-05-07 |
EP1794283A1 (en) | 2007-06-13 |
EP1794283B1 (en) | 2016-04-13 |
US8551473B2 (en) | 2013-10-08 |
CA2580949A1 (en) | 2006-04-06 |
CN101603021B (zh) | 2013-04-24 |
EP3050960A1 (en) | 2016-08-03 |
PL1794283T3 (pl) | 2016-10-31 |
CN100537740C (zh) | 2009-09-09 |
AU2005288751A1 (en) | 2006-04-06 |
EA012968B1 (ru) | 2010-02-26 |
CN101603021A (zh) | 2009-12-16 |
WO2006035218A1 (en) | 2006-04-06 |
GB0421448D0 (en) | 2004-10-27 |
US20130011368A1 (en) | 2013-01-10 |
EP3050960B1 (en) | 2017-12-13 |
CA2580949C (en) | 2017-07-25 |
GB2418431A (en) | 2006-03-29 |
US20110158949A1 (en) | 2011-06-30 |
ZA200702398B (en) | 2008-10-29 |
NO20072210L (no) | 2007-04-27 |
CN101027387A (zh) | 2007-08-29 |
AU2005288751B2 (en) | 2010-12-23 |
ES2654246T3 (es) | 2018-02-12 |
ES2568955T3 (es) | 2016-05-05 |
NZ553858A (en) | 2009-01-31 |
EA200700613A1 (ru) | 2007-10-26 |
PL3050960T3 (pl) | 2018-05-30 |
JP2008514582A (ja) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5577020B2 (ja) | 代謝活性を有する微生物及びその製造方法 | |
JP2018111711A (ja) | リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 | |
US20190070229A1 (en) | Composition comprising a lactic acid bacteria for preventing and treating vaginosis and the use thereof | |
US20100074878A1 (en) | Probiotic bacterium: lactobacillus fermentum | |
US12036252B2 (en) | Pairing probiotics and prebiotics, methods for growth and use, separately and in combination | |
KR20040018319A (ko) | 락토바실러스 카제이 균주 κε01에서 유래된 정장제 화합물 | |
US20140314719A1 (en) | IBS Treatment | |
TW202002963A (zh) | 用於尿石素(urolithin)化合物之生物合成製備的組合物及方法以及其用途 | |
EP3329927B1 (en) | Ibs treatment with probiotics | |
CN114921383A (zh) | 一种具有清除胆固醇功能的益生菌制剂及其制备方法 | |
KR101164512B1 (ko) | 비피도박테리움 슈도카테눌라튬 spm1204 유산균 또는 이의 배양물을 유효성분으로 하는 가축용 생균제 조성물 | |
EP3524051A1 (en) | Matricial microencapsulation compositions | |
Subhashree | Development of plant base probiotic nutritional supplement to enhance gut probiotic microflora | |
FOODS | 3rd INTERNATIONAL PROBIOTIC CONFERENCE–SPEAKER’S ABSTRACTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080924 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120316 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120326 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120420 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130218 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130422 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130430 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130523 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130625 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140331 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140701 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140707 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5577020 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |